Related Experiment Videos
DNA methylation differences associated with tumor tissues identified by genome scanning analysis
1Department of Biochemistry and Molecular Biology, Urologic Cancer Research Laboratory, Los Angeles, California, 90033, USA.
Genomics
|November 4, 1998
Summary
This study reveals that DNA methylation patterns in cancer cells differ significantly from normal cells, affecting not only known genes but also previously unidentified ones. These epigenetic changes in CpG islands are widespread in tumors, indicating a broader role in cancer development.
Area of Science:
- Molecular Biology
- Cancer Epigenetics
- Genomics
Background:
- Most cancer DNA methylation research focuses on known tumor suppressor genes.
- This approach may underestimate the role of epigenetic alterations in unknown cancer-related genes.
- Genetic alterations like deletions and mutations may miss genes affected primarily by methylation.
Purpose of the Study:
- To investigate DNA methylation patterns in cancer beyond known tumor suppressor genes.
- To identify novel CpG islands affected by methylation in various cancer types.
- To explore the prevalence and location of DNA methylation changes in cancerous tissues.
Main Methods:
- Utilized methylation-sensitive arbitrarily primed-polymerase chain reaction (PCR) for genomic screening.
- Analyzed DNA methylation patterns in white blood cells (WBCs) and tumor tissues (colon, bladder, prostate).
- Performed direct sequencing of altered DNA bands to identify CpG islands and gene regions.
Main Results:
- Identified significant DNA methylation changes in cancer cells compared to normal tissues and WBCs.
- Observed considerable variation in methylation patterns among different tumors, suggesting variable penetrance.
- Discovered that hypermethylation affects not only gene promoters but also actively transcribed gene regions.
Conclusions:
- DNA methylation is a significant epigenetic factor in cancer, impacting a broader range of genes than previously recognized.
- CpG island hypermethylation in cancer is not limited to regulatory regions but extends to transcribed areas.
- This epigenetic dysregulation highlights the potential for novel diagnostic and therapeutic targets in cancer.